Cargando…
Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821]
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630038/ https://www.ncbi.nlm.nih.gov/pubmed/37873727 http://dx.doi.org/10.1016/j.neo.2022.100843 |
| _version_ | 1784823514895745024 |
|---|---|
| author | Li, Hongchang Su, Xianhao Li, Jindong Liu, Weiyan Pan, Gaofeng Mao, Anwei Liu, Jiazhe Zhang, Qing Rao, Longhua Xie, Xiaofeng Sheng, Xia |
| author_facet | Li, Hongchang Su, Xianhao Li, Jindong Liu, Weiyan Pan, Gaofeng Mao, Anwei Liu, Jiazhe Zhang, Qing Rao, Longhua Xie, Xiaofeng Sheng, Xia |
| author_sort | Li, Hongchang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9630038 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Neoplasia Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96300382022-11-14 Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821] Li, Hongchang Su, Xianhao Li, Jindong Liu, Weiyan Pan, Gaofeng Mao, Anwei Liu, Jiazhe Zhang, Qing Rao, Longhua Xie, Xiaofeng Sheng, Xia Neoplasia Erratum/Corrigendum Neoplasia Press 2022-10-22 /pmc/articles/PMC9630038/ /pubmed/37873727 http://dx.doi.org/10.1016/j.neo.2022.100843 Text en © 2022 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Erratum/Corrigendum Li, Hongchang Su, Xianhao Li, Jindong Liu, Weiyan Pan, Gaofeng Mao, Anwei Liu, Jiazhe Zhang, Qing Rao, Longhua Xie, Xiaofeng Sheng, Xia Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821] |
| title | Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821] |
| title_full | Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821] |
| title_fullStr | Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821] |
| title_full_unstemmed | Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821] |
| title_short | Corrigendum to Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1 α/miR-494/Survivin signaling pathway [Volume 32 Number xxx Month 2022 pp. 100821] |
| title_sort | corrigendum to hypoxia induces docetaxel resistance in triple-negative breast cancer via the hif-1 α/mir-494/survivin signaling pathway [volume 32 number xxx month 2022 pp. 100821] |
| topic | Erratum/Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630038/ https://www.ncbi.nlm.nih.gov/pubmed/37873727 http://dx.doi.org/10.1016/j.neo.2022.100843 |
| work_keys_str_mv | AT lihongchang corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT suxianhao corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT lijindong corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT liuweiyan corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT pangaofeng corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT maoanwei corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT liujiazhe corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT zhangqing corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT raolonghua corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT xiexiaofeng corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 AT shengxia corrigendumtohypoxiainducesdocetaxelresistanceintriplenegativebreastcancerviathehif1amir494survivinsignalingpathwayvolume32numberxxxmonth2022pp100821 |